THERAPY DOSSIER · th-4e997e9f3d00

Recombinant human milk fat globule-EGF factor 8 (rhMFG-E8)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23056336 ↗2012Reported benefit

Recombinant human MFG-E8 attenuates intestinal injury and mortality in severe whole body irradiation in rats.

RatRadiationSprague-DawleyMalen = Histology and morphometry n=4 per group; MFG-E8 gene expres…Subcutaneous166 micrograms/kg body weight in vivo; 0.5 micrograms/mL in…First dose 6 h after whole body irradiation; in vitro 1 h before and immediatel…

Model: Whole body irradiation at 10 Gy from a Cesium-137 source delivered at approximately 2.5 Gy/min over 4 min, previously determined as the dose lethal to 70 per cent of animals at 21 days; in vitro IEC-6 rat small intestinal epithelial cells irradiated at 8 Gy

Subcutaneous rhMFG-E8 started 6 h after 10 Gy whole body irradiation improved 21-day survival from 31 to 75 per cent and reduced the radiation injury intestinal mucosal damage score by 36 per cent, with increased p53, p21 and Bcl-2 expression.

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…